Table 4 Cytogenetic abnormalities of AML patients stratified by age groups

Genes mutation total events (mean)

2.02

1.94

2.37

0.034*

 TET2

164 (50.5%)

136 (50.7%)

28 (49.1%)

0.8238

 ASXL1

62 (19.1%)

46 (17.2%)

16 (28.1%)

0.057^#

 CEBPA

56 (17.2%)

49 (18.3%)

7 (12.3%)

0.2758

 FLT3

53 (16.3%)

45 (16.8%)

8 (14.0%)

0.609

 DNMT3A

44 (13.5%)

35 (13.1%)

9 (15.8%)

0.584

 NRAS

39 (12.0%)

32 (11.9%)

7 (12.3%)

0.943

 NPM1

36 (11.1%)

29 (10.8%)

7 (12.3%)

0.7498

 RUNX1

25 (7.7%)

17 (6.3%)

8 (14.0%)

0.0478*

 IDH1

22 (6.8%)

19 (7.1%)

3 (5.3%)

0.618

 IDH2

22 (6.8%)

13 (4.9%)

9 (15.8%)

0.0028**

 KIT

19 (5.8%)

18 (6.7%)

1 (1.8%)

0.147^#

 ETV6

9 (2.8%)

7 (2.6%)

2 (3.5%)

0.7079

 TP53

9 (2.8%)

4 (1.5%)

5 (8.8%)

0.0024**

 WT1

8 (2.5%)

6 (2.2%)

2 (3.5%)

0.574

 U2AF1

8 (2.5%)

6 (2.2%)

2 (3.5%)

0.574

 PHF6

8 (2.5%)

6 (2.2%)

2 (3.5%)

0.574

 EZH2

7 (2.2%)

7 (2.6%)

0 (0.0%)

NA

 TTN

7 (2.2%)

5 (1.9%)

2 (3.5%)

0.4378

 SF3B1

7 (2.2%)

3 (1.1%)

4 (7.0%)

0.005**

 SRSF2

4 (1.2%)

3 (1.1%)

1 (1.8%)

0.693

 JAK2

3 (0.9%)

2 (0.7%)

1 (1.8%)

0.4698

DNA methylation (frequency, %)

252 (77.5%)

202 (75.4%)

50 (87.7%)

0.0425*

RNA spliceosome (frequency, %)

20 (6.2%)

12 (4.5%)

8 (14.0%)

0.006399**

Chromatin remodelling (frequency, %)

69 (21.2%)

53 (19.8%)

16 (28.1%)

0.164379^#

Transcriptional deregulation (frequency, %)

89 (27.04%)

72 (26.9%)

17 (28.8%)

0.649175

Activated signalling (frequency, %)

118 (36.3%)

101 (37.7%)

17 (28.8%)

0.262345